Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Holistic Lifestyle mHealth Intervention for Risk Reduction of Type 2 Diabetes Mellitus in Young Adults

17. mai 2026 oppdatert av: Anmol Ayaz, Fatima Jinnah Women University

Effectiveness of Holistic Lifestyle mHealth Intervention for Risk Reduction of Type 2 Diabetes Mellitus in Young Adults: A Randomized Controlled Trial

The goal of this clinical trial (randomized controlled trial) is to examine the effectiveness of a holistic lifestyle mHealth intervention in reducing the risk of type 2 diabetes mellitus.

The study focuses on young adults aged 20-35 years, recruited from public and private universities in Rawalpindi and Islamabad, who meet the defined inclusion criteria.

The main questions it aims to answer are:

Does a holistic lifestyle mHealth intervention significantly reduce the risk of type 2 diabetes ? Does the intervention improve overall health-related quality of life and lifestyle behaviors, including diet, physical activity, and stress management?

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

Researchers will compare participants receiving the holistic lifestyle mHealth intervention (based on "Eat Well, Move More, Stress Less") with a control group receiving standard care or basic health guidance to see if the intervention leads to greater reduction in diabetes risk and improved health outcomes.

Participants will:

Use a culturally tailored mHealth application designed for the Pakistani context Follow lifestyle recommendations focused on diet, physical activity, and stress management Engage with intervention content based on the three core pillars: Eat Well, Move More, Stress Less Participate in periodic assessments, including health measurements and questionnaires Provide feedback on their experience and adherence to the intervention

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Punjab Province
      • Rawalpindi, Punjab Province, Pakistan, 46000
        • University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Young adults aged between 20-35 years, as defined by the WHO.
  • At risk of diabetes based on self-reported family history or lifestyle habits.
  • Participants who are willing to engage in the mHealth intervention program.
  • Own a smartphone and are familiar with using mobile apps.
  • Complete the informed consent process, agreeing to follow the study protocol, including survey completion and health assessment.

Exclusion Criteria:

  • Individuals diagnosed with chronic mental or physical illnesses
  • Individuals with hearing or vision loss so severe that they could not access the mobile health intervention.
  • Pregnant women or women who plan on becoming pregnant during the study.
  • Individuals who are already taking part in an equivalent diabetes or health programme.
  • Individuals who are not willing to provide consent.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Intervensjonsgruppe
The main components of the holistic mHealth intervention include the following: nutritional education, promotion of physical activity, sleep education, and behavioral health support. The integration of these components in mHealth promotes a holistic lifestyle through enhancing overall health-related quality of life.
Andre navn:
  • mHealth-appen
  • mhealth Intervention
  • Holistic Intervention

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Improved quality of Life
Tidsramme: 6-8 weeks

Measured using a validated tool, the Short Form Health Survey (SF-36), assessed at baseline and post-intervention. The primary endpoint is the difference in mean risk scores between the intervention and control groups.

score ≤ 44 indicates weak, 45-63 indicate medium, ≥ 64 indicate good.

6-8 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Secondary outcome measures include changes in blood glucose level
Tidsramme: 8 weeks

Diabetes risk assessment is assessed through RAPID (Risk Assessment of Pakistani Individual for Diabetes) .

Changes in blood glucose levels assessd through HbA1c measured in mg/dL at baseline and post-intervention.

8 weeks
Food literacy
Tidsramme: 8 weeks
Food literacy measured by using Self-Perceived Food Literacy Scale Short Form Scoing : <30.6 indicates inadequate-limited food literacy; >31 indicates adequate-excellent food literacy.
8 weeks
Eating Behavior
Tidsramme: 8 weeks
Eating Behavior measured by using Self-Regulation of Eating Behavior Questionnaire for Adults. Scoring: <2.8 indicate Low level, 2.8 to 3.6 indicate Medium>3.6High
8 weeks
Physical Health
Tidsramme: 8 weeks
weight will be combined to report BMI in kg/m^2.
8 weeks
sleep quality
Tidsramme: 8 weeks

Sleep Quality measured by Pittsburgh Sleep Quality Index (PSQI) Scoring

:0 - No sleep difficulties; 5 or higher - Poor sleep quality

8 weeks
Psychological Distress
Tidsramme: 8 weeks

Psychological Distress will be measured by using Depression, Anxiety and Stress Scale (DASS-21)

Scoring:

Depression : 0-9 normal ,14-20 moderate , 28+ severe Anxiety : 8-9 mild , 10-14 moderate Stress: 15-18 mild, 19-25 moderate

8 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. mai 2026

Primær fullføring (Antatt)

30. juli 2026

Studiet fullført (Antatt)

30. desember 2026

Datoer for studieregistrering

Først innsendt

26. april 2026

Først innsendt som oppfylte QC-kriteriene

17. mai 2026

Først lagt ut (Faktiske)

22. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-dentified participant data underlying the published results may be made available upon reasonable request. Shared data may include demographic variables, outcome measures, and analyzable datasets relevant to the study objectives.

Data requests may be submitted to the principal investigator. Access will be considered for researchers with methodologically sound proposals and subject to institutional ethical approval and data use agreements.

IPD-delingstidsramme

Data and supporting documents will be available beginning 6 months after publication of the primary outcomes and will remain available for up to 5 years.

Tilgangskriterier for IPD-deling

Access may be granted to researchers with methodologically sound proposals for academic or scientific purposes. Requests should be directed to the principal investigator and may require institutional ethical approval and a signed data use agreement.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere